Assuntos
Deferasirox , Quelantes de Ferro , Sistema de Registros , Talassemia , Humanos , Deferasirox/uso terapêutico , Deferasirox/administração & dosagem , Talassemia/terapia , Masculino , Feminino , Quelantes de Ferro/uso terapêutico , Quelantes de Ferro/administração & dosagem , Adolescente , França/epidemiologia , Criança , Transfusão de Sangue , Puberdade/efeitos dos fármacos , Administração Oral , Triazóis/administração & dosagem , Triazóis/uso terapêutico , Terapia por QuelaçãoAssuntos
Transplante de Células-Tronco Hematopoéticas , Talassemia , Humanos , Bussulfano/uso terapêutico , Estudos Retrospectivos , Quimerismo , Transplante de Células-Tronco Hematopoéticas/métodos , Transplante de Células-Tronco , Talassemia/terapia , França , Condicionamento Pré-Transplante/métodos , Sociedades MédicasRESUMO
OBJECTIVE: Childhood and adolescent cancer can result in high burden of distressing symptoms, particularly in high-risk malignancies. The Symptom Screening in Pediatrics Tool (SSPedi) is a reliable and valid approach to measure bothersome symptoms in paediatric patients receiving cancer treatments. Objective was to describe the feasibility of using SSPedi administration among paediatric patients with high-risk malignancies. METHODS: We conducted a single-centre, cross-sectional study of patients aged 8-18 years with high-risk malignancies in a French paediatric oncology unit. Patients self-reported the degree of bothersome symptoms using SSPedi and difficulty with SSPedi completion. The total SSPedi Score ranging from 0 to 60 (where 60 is worst) and most common moderately bothersome symptoms (scored ≥2 on 0-4 Likert Scale) were described. Feasibility was defined as more than 75% of patients agreeing to participate and more than 90% completion of SSPedi questionnaire. RESULTS: Out of 16 patients approached, 1 declined participation. Median age was 13 years (IQR 8-19). All were able to self-report SSPedi without difficulty. Patients experienced a median number of 6 (range 0-15) bothersome symptoms (score >0). The mean total SSPedi Score was 12 (SD=9.4). Most common moderately bothersome symptoms were pain (8/15), changes in hunger (8/15) and feeling tired (7/15). CONCLUSION: Patient-reported symptom assessment among children and adolescents with high-risk malignancies is feasible using SSPedi. These patients experience a high burden of bothersome symptoms.